The Biggest Question in Weight Loss
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the two most prescribed weight loss drugs in the world. Together they represent a $50+ billion market. The question everyone asks: which one should I take?
This guide compares them head-to-head on every metric that matters — weight loss, side effects, cardiovascular data, cost, muscle preservation, and practical considerations.
The Quick Answer
| If your priority is… | Choose | Why |
|---|---|---|
| Maximum weight loss | Tirzepatide | 22.5% vs 14.9% body weight loss |
| Proven heart protection | Semaglutide | SELECT trial: 20% MACE reduction |
| Fewest GI side effects | Tirzepatide | GIP may buffer GI symptoms |
| Oral contraceptive use | Semaglutide | Tirzepatide reduces OC absorption |
| Lowest pharmaceutical cost | Tirzepatide | Zepbound ~$1,060 vs Wegovy ~$1,300 |
| Lowest research-grade cost | Semaglutide | ~$80–150/mo vs ~$100–200/mo |
| Type 2 diabetes | Either | Both approved; tirzepatide has better glycemic data |
| Longest track record | Semaglutide | Approved first, more post-market data |
Head-to-Head Comparison
The Master Table
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual agonist |
| FDA approval | Diabetes (2017), Weight (2021) | Diabetes (2022), Weight (2023) |
| Max dose | 2.4 mg/week (Wegovy) | 15 mg/week (Zepbound) |
| Weight loss (max dose) | 14.9% at 68 weeks | 22.5% at 72 weeks |
| Titration period | 16 weeks to max dose | 20 weeks to max dose |
| Administration | Weekly SC injection | Weekly SC injection |
| Oral form | Yes (Rybelsus — daily tablet) | No |
| CV outcomes data | Yes (SELECT: 20% MACE reduction) | Ongoing (SURPASS-CVOT) |
| A1c reduction | 1.5–2.0% | 2.0–2.5% |
| Nausea rate | 40–50% | 25–35% |
| Lean mass loss | ~40% of weight lost | ~30% of weight lost |
| OC interaction | No | Yes (reduces absorption) |
| Retail cost | ~$1,300/mo (Wegovy) | ~$1,060/mo (Zepbound) |
| Research-grade cost | ~$80–150/mo | ~$100–200/mo |
The Science: Why Tirzepatide Wins on Weight Loss
Single vs Dual Agonism
Semaglutide targets one receptor. Tirzepatide targets two. This isn’t just “more is better” — the GIP receptor adds a qualitatively different mechanism of action.
What GLP-1 does (both drugs):
- Suppresses appetite centrally (hypothalamic signaling)
- Delays gastric emptying (you feel full longer)
- Enhances insulin secretion (glucose-dependent)
What GIP adds (tirzepatide only):
- Enhances fat metabolism in adipose tissue
- Improves beta-cell function beyond GLP-1 alone
- May buffer GI side effects (GIP has gastric-protective properties)
- Improves lipid metabolism
The result: tirzepatide produces weight loss from both reduced intake (GLP-1) and improved metabolic processing (GIP). Semaglutide relies primarily on reduced intake.
The SURPASS-2 Head-to-Head
The most important comparison study: tirzepatide 15 mg vs semaglutide 1 mg in Type 2 diabetes.
| Outcome | Semaglutide 1 mg | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg |
|---|---|---|---|---|
| A1c reduction | -1.86% | -2.01% | -2.24% | -2.30% |
| Weight loss | -5.7 kg | -7.6 kg | -9.3 kg | -11.2 kg |
| A1c < 7% achieved | 79% | 82% | 86% | 86% |
Important caveat: The semaglutide dose (1 mg) was submaximal — the weight management dose is 2.4 mg. However, the magnitude of tirzepatide’s advantage (nearly double the weight loss at 15 mg) exceeds what semaglutide dose adjustment alone would explain.
The Science: Why Semaglutide Wins on Cardiovascular Data
The SELECT Trial
The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) is the reason semaglutide has a safety advantage tirzepatide can’t currently match:
- 17,604 participants with established cardiovascular disease and BMI ≥27
- Semaglutide 2.4 mg vs placebo for mean 40 months
- Primary outcome: 20% reduction in MACE (heart attack, stroke, cardiovascular death)
- This benefit was independent of weight loss — cardiovascular protection came from direct anti-inflammatory and anti-atherosclerotic effects
No other GLP-1 or GIP agonist has demonstrated this level of cardiovascular protection in an obesity population. Tirzepatide’s SURPASS-CVOT trial is ongoing — results are expected but not yet available.
What this means practically: If you have cardiovascular disease, cardiovascular risk factors, or a family history of heart attack/stroke, semaglutide has proven protection that tirzepatide has not yet demonstrated.
Side Effect Comparison
GI Side Effects
Both drugs cause gastrointestinal side effects — the most common reason for discontinuation. Proper titration reduces severity significantly.
| Side Effect | Semaglutide | Tirzepatide | Notes |
|---|---|---|---|
| Nausea | 40–50% | 25–35% | Most common, usually first 4–8 weeks |
| Diarrhea | 25–30% | 15–25% | Usually mild, self-limiting |
| Constipation | 20–25% | 10–15% | Delayed gastric emptying effect |
| Vomiting | 15–20% | 10–15% | Dose-dependent |
| Abdominal pain | 10–15% | 5–10% | Usually with meals |
Why tirzepatide may be better tolerated: GIP has gastric-protective properties — it reduces gastric acid secretion and has trophic effects on gastric mucosa. The GIP component may partially buffer the GI distress caused by GLP-1 activation.
Serious Side Effects (Rare)
| Risk | Semaglutide | Tirzepatide |
|---|---|---|
| Pancreatitis | Rare (0.1–0.3%) | Rare (0.1–0.3%) |
| Gallbladder events | Increased risk | Increased risk |
| Thyroid C-cell tumors | Boxed warning (rodent data) | Boxed warning (rodent data) |
| Acute kidney injury | Rare (dehydration-related) | Rare (dehydration-related) |
| Suicidal ideation | Under investigation (no causal link established) | Under investigation |
The Muscle Loss Problem
Every GLP-1 drug causes lean mass loss alongside fat loss. This is the most important long-term consideration:
| Metric | Semaglutide | Tirzepatide |
|---|---|---|
| Lean mass as % of total weight lost | ~40% | ~30% |
| Study | STEP 1 DEXA substudy | SURMOUNT-1 body composition data |
Tirzepatide appears to preserve lean mass slightly better than semaglutide — possibly because GIP’s effects on fat metabolism favor fat-specific weight loss over indiscriminate weight loss.
Non-negotiable for both drugs:
- Resistance training 3–4x/week
- Protein 1.2–1.6 g/kg/day across 3–4 meals
- Creatine 5g/day
- Don’t crash calories — let the drug suppress appetite naturally
Cost Reality
Pharmaceutical Pricing
| Product | Monthly Retail | With Savings Card | With Insurance |
|---|---|---|---|
| Wegovy (semaglutide 2.4 mg) | ~$1,300 | Varies | $0–50 copay |
| Ozempic (semaglutide 1 mg) | ~$1,000 | As low as $25 | $0–50 copay |
| Zepbound (tirzepatide 15 mg) | ~$1,060 | Lilly vial program ~$550 | $0–50 copay |
| Mounjaro (tirzepatide 15 mg) | ~$1,200 | Varies | $0–50 copay |
Research-Grade Pricing
| Peptide | Monthly Cost | Notes |
|---|---|---|
| Semaglutide | $80–150 | Requires reconstitution, injection experience |
| Tirzepatide | $100–200 | Same requirements |
Compounded Versions
Compounded semaglutide availability has been restricted as the FDA shortage resolves. Check current FDA guidance — this is a rapidly changing situation. See our Peptide Legality Guide for details.
Practical Decision Guide
By Patient Profile
| Profile | Recommended | Rationale |
|---|---|---|
| BMI 30+, no comorbidities | Tirzepatide | More weight loss, FDA-approved |
| BMI 30+, Type 2 diabetes | Either (tirzepatide slightly better) | Better A1c reduction with tirzepatide |
| BMI 27+, cardiovascular disease | Semaglutide | Only option with proven MACE reduction |
| BMI 27+, cardiovascular risk factors | Semaglutide | SELECT trial applies here |
| Women on oral contraceptives | Semaglutide | Tirzepatide reduces OC absorption |
| Sensitive to GI side effects | Tirzepatide | Better tolerated at equivalent efficacy |
| Want oral option | Semaglutide | Rybelsus (oral tablet) available |
| Budget-conscious (pharmaceutical) | Tirzepatide | Zepbound slightly cheaper + vial program |
| Budget-conscious (research-grade) | Semaglutide | Cheaper research-grade sources |
| Already on semaglutide, plateaued | Consider switching to tirzepatide | Dual mechanism may break plateau |
Switching Between Drugs
Semaglutide → Tirzepatide:
- Washout: 2–4 weeks (semaglutide half-life ~1 week)
- Start tirzepatide at 2.5 mg regardless of previous semaglutide dose
- Expect GI side effects to recur during transition
Tirzepatide → Semaglutide:
- Washout: 2–4 weeks (tirzepatide half-life ~5 days)
- Start semaglutide at 0.25 mg standard titration
- Weight loss may slow (expected — semaglutide is less potent)
What About Retatrutide?
Retatrutide is the next-generation triple-agonist (GLP-1 + GIP + glucagon) that produced 24.2% weight loss at 48 weeks in Phase 2 — faster than tirzepatide achieved at 72 weeks. It is not yet FDA-approved and is available only as a research chemical.
For the full comparison including retatrutide and AOD-9604, see our Weight Loss Peptides Compared guide.
Related Protocols
- Semaglutide Protocol — full dosing, titration, and management guide
- Tirzepatide Protocol — dual-agonist protocol with OC interaction details
- Retatrutide Protocol — triple-agonist investigational protocol
- Weight Loss Peptides Compared — all weight loss options compared
- Reconstitution Calculator — exact unit counts for research-grade dosing
Frequently Asked Questions
Which causes more weight loss, Ozempic or Mounjaro? +
Mounjaro (tirzepatide) produces significantly more weight loss than Ozempic (semaglutide). At maximum doses, tirzepatide achieves approximately 22.5% total body weight loss vs 14.9% for semaglutide. The SURPASS-2 trial showed tirzepatide 15 mg produced roughly double the weight loss of semaglutide 1 mg head-to-head. Even accounting for the semaglutide dose being submaximal, the difference is substantial.
Is Ozempic or Mounjaro safer? +
Both have similar safety profiles. GI side effects (nausea, diarrhea, constipation) are common with both but may be slightly less frequent with tirzepatide at equivalent weight loss levels. The key safety difference: semaglutide has proven cardiovascular protection (SELECT trial — 20% MACE reduction). Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. If cardiovascular risk is a concern, semaglutide has the evidence advantage.
Can I switch from Ozempic to Mounjaro? +
Yes. A washout period of 2–4 weeks is recommended. Start tirzepatide at the standard 2.5 mg starting dose regardless of your previous semaglutide dose — the drugs target different receptors and there is no direct dose equivalency. GI side effects may recur during the transition as your body adjusts to the new drug.
Why is tirzepatide more effective than semaglutide? +
Tirzepatide is a dual-agonist — it activates both the GLP-1 receptor (like semaglutide) AND the GIP receptor. GIP enhances fat metabolism in adipose tissue, improves beta-cell function, and may buffer GI side effects. This dual mechanism produces weight loss from both reduced caloric intake (GLP-1) and improved metabolic fat processing (GIP). Semaglutide targets GLP-1 alone.
Which is cheaper, semaglutide or tirzepatide? +
At pharmaceutical retail prices, they are similar: semaglutide (Wegovy) ~$1,300/month, tirzepatide (Zepbound) ~$1,060/month. Insurance coverage varies and determines actual out-of-pocket cost. Research-grade pricing: semaglutide ~$80–150/month, tirzepatide ~$100–200/month. Compounded semaglutide availability has been restricted by FDA actions since 2024.
Do I need a prescription for semaglutide or tirzepatide? +
Both are FDA-approved prescription medications. Ozempic and Mounjaro require a prescription for diabetes. Wegovy and Zepbound require a prescription for weight management (BMI 30+ or BMI 27+ with weight-related comorbidity). Research-grade versions are available without prescription but are labeled 'not for human consumption.' Telehealth services can prescribe both.